Soins de support, cognition, qualité de vie et métastases cérébrales
| Autor: | Marie Blonski, S. Taillibert, F. Bonnetain, E. Le Rhun, P. Auquier, H. Taillia, Catherine Belin, A. Tallet, D. Varin, D. Delgadillo, L. Taillandier, N. Jouniaux Delbez |
|---|---|
| Přispěvatelé: | Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), SALZET, Michel, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) |
| Jazyk: | francouzština |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Activities of daily living media_common.quotation_subject [SDV]Life Sciences [q-bio] Disease 03 medical and health sciences Epilepsy 0302 clinical medicine Quality of life Medicine Combined Modality Therapy Radiology Nuclear Medicine and imaging Adverse effect Intensive care medicine ComputingMilieux_MISCELLANEOUS media_common business.industry Cognition medicine.disease 3. Good health [SDV] Life Sciences [q-bio] Oncology 030220 oncology & carcinogenesis business 030217 neurology & neurosurgery Autonomy |
| Zdroj: | Cancer Radiothérapie Cancer Radiothérapie, Elsevier Masson, 2015, 19 (1), pp.55-60. ⟨10.1016/j.canrad.2014.11.003⟩ Cancer/Radiothérapie Cancer/Radiothérapie, 2015, 19 (1), pp.55-60. ⟨10.1016/j.canrad.2014.11.003⟩ |
| ISSN: | 1278-3218 1769-6658 |
| Popis: | Brain metastases impact on the survival of the patients, but on their quality of life as well. The objective of the management of these patients is then double. Currently, due to medical advances, survivals tend to improve, especially for some tumor subtypes. During the course of the disease, different neurological signs and symptoms can be observed according to the location, the number and the volume of the metastase(s). Patients and caregivers are especially worried about the loss of autonomy and cognitive impairments. A permanent dialogue, during the course of the disease, is mandatory, in order to adapt the management to the objectives determined by the patients and the medical team. These objectives may vary according to the objective response rates of the disease to anticancer therapies, according to the impact of the disease and its management in daily living. Anticancer therapies and supportive care must be appreciated according to their impact on the survival, on the preservation of the functional independence and the quality of life of the patient, on their abilities to preserve the neurological status and delay the apparition of new neurological signs and symptoms, and their adverse events. Supportive care, cognition and quality of life should be regularly evaluated and adapted according to the objectives of the management of brain metastases patients. Different approaches are described in this paper. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect